Skip to main content

Health Minister Jane Philpott speaks during Question Period in the House of Commons on Monday.

Sean Kilpatrick/THE CANADIAN PRESS

Federal Health Minister Jane Philpott says she's concerned that a physician with financial ties to Big Pharma was allowed to vote on new national standards for prescribing opioids.

McMaster University received just less than $500,000 in federal funding in 2015 to revise Canada's out-of-date prescribing guidelines. In their application for funding, officials at McMaster pledged that all members of the voting panel will be required to have no financial conflicts of interest.

However, the officials did not honour that pledge. The Globe and Mail has reported that Sol Stern, a family doctor in Oakville, Ont., and one of 13 panel members who voted on the standards, has been a paid speaker and advisory board member for drug companies, including the pharmaceutical giant whose pain pill triggered Canada's deadly opioid epidemic.

Story continues below advertisement

Read more: Doctor's pharma links raise fears of bias on opioid panel

"Well, certainly it's concerning," Dr. Philpott told reporters on Monday when asked about Dr. Stern's drug industry ties. "We have made very specific requests to McMaster University to be absolutely sure that there were no conflicts of interest in the participants who took part in the survey."

Jason Busse, an associate professor at McMaster's department of anesthesia and co-lead of the group that drafted the standards, said in an earlier e-mail response to The Globe that the group made an exception for Dr. Stern because his industry-sponsored talks represented a "balanced approach" to opioids. Dr. Stern "reassured us he had no overt bias either strongly in favour or strongly opposed to opioids for chronic pain," Dr. Busse said.

Dr. Stern received remuneration from four drug companies, including Purdue Pharma, maker of the prescription painkiller OxyContin, according to his declaration form posted online last week. A continuing Globe investigation has traced the roots of Canada's opioid epidemic to the introduction of OxyContin in 1996.

The decision to approve Dr. Stern as a panel member has shrouded the new prescribing standards in controversy. Medical experts said physicians who get paid to produce educational seminars about opioids by a company that makes the drugs have a conflict and should not be allowed to vote on guidelines that advise doctors on how to prescribe painkillers.

"Anyone who received money from Purdue at any time from 2000 onwards should not have been allowed any input on the guidelines," said Paul Cary, a family doctor in Cambridge, Ont., who treats many patients dependent on opioids.

The standards, unveiled last week by McMaster's Michael G. DeGroote National Pain Centre, are aimed at reversing practices developed two decades ago, when doctors began prescribing opioids to relieve moderate to severe pain as pharmaceutical companies promoted their benefits. Purdue paid doctors, known as key opinion leaders, to help spread the word in the medical community that OxyContin posed a lower threat of abuse and dependence to patients than other painkillers. Those claims turned out to be untrue: Purdue and three of its executives paid $634.5-million (U.S.) in 2007 to settle criminal and civil charges against them for misbranding OxyContin as less addictive than other medications.

Story continues below advertisement

McMaster officials had promised Health Canada that they would avoid a repeat of what happened in 2010, when one-third of the panel members working on an earlier version of the prescribing standards had ties to drug companies.

Dr. Philpott said she learned only recently about the problem with the latest version.

"I am still working to get more information to determine what our next steps will be on that," she said.

Report an error Editorial code of conduct
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

Cannabis pro newsletter